GW Pharma Marijuana Drug Confirms Seizure Benefit in Second Pivotal Trial
GW Pharmaceuticals (GWPH) announced positive results Monday from a second, pivotal clinical trial involving children with a severe form of epilepsy treated with its experimental marijuana-based drug.
Shares of GW Pharma are up 16% to $96.52 in Monday pre-market trading.
In the phase III study, treatment with the GW Pharma drug epidiolex resulted in a 44% reduction in monthly drop seizures compared to a 22% reduction for placebo. The difference was statistically significant.
The study enrolled 171 children (average age: 15) with Lennox-Gastaut Syndrome. Despite taking an average of three medicines to reduce seizures, the patients were still having a median of 74 drop seizures per month. The study added Epidiolex or placebo on top of the patients' other anti-seizure medicines.
Diarrhea, sleepiness, decreased appetite, fever and vomiting were the most common adverse events reported in the study, although a majority were mild to moderate. Twenty patients on epidiolex...
This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.
Follow us on Instagram
Connect with us on Linkedin